{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-001679","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.429297+00:00","generated_at":"2026-06-17T21:17:23.216145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio Pharmaceuticals reports 2022 net loss of $11.5M and provides pipeline updates","bullets":["Cash at Dec 31, 2022: $11.8M, down from $24.1M a year earlier; funds operations through Q4 2023.","Net loss of $11.5M ($10.10/share) vs $13.3M ($12.43/share) in 2021; R&D expenses fell 21% to $7.0M.","DMC recommended proceeding to second cohort of PH-762 Phase 1b for advanced melanoma after no safety issues.","FDA cleared partner AgonOx to start Phase 1 ACT trial with PH-762 for solid tumors; PH-894 IND-enabling studies complete.","Robert Bitterman appointed President and CEO (previously interim CEO); Nasdaq compliance regained after reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-001679","json":"https://secwatch.observer/filing/0001683168-23-001679.json","markdown":"https://secwatch.observer/filing/0001683168-23-001679.md","text":"https://secwatch.observer/filing/0001683168-23-001679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/0001683168-23-001679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:17:23.216145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2b6661ed50d897e4ff1d8fdcd0e0e21cc8720c4","claim":"Phio Pharmaceuticals Corp. reported the year ended December 31, 2022 results: net income approximately $11.5 million, or $10.10 per share, EPS $10.10 per share.","evidence_excerpt":"Net loss decreased 14% to approximately $11.5 million, or $10.10 per share, for the year ended December 31, 2022, compared with $13.3 million, or $12.43 per share, for the year ended December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/0001683168-23-001679-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"approximately $11.5 million, or $10.10 per share"},{"label":"EPS","value":"$10.10 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}